Embracing Differences: Our journey to diversity, equity, and inclusion
Embracing Differences: Our journey to diversity, equity, and inclusion
Search
The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions | Boehringer Ingelheim US
The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions
Nick Gollop
Nick Gollop loves making a difference for patients and their families as a Senior Global Clinical Programme Leader in Clinical Development.
Looking Ahead at Recruitment in the Biopharma Industry
Looking Ahead at Recruitment in the Biopharma Industry
Scleroderma
Scleroderma
Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US
Click here to find out more how the Boehringer Ingelheim veterinary scholars program has helped 3,500 people over 30 years. Read five of their stories here.
Clinical Development and Operations
Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.
Generalized Pustular Psoriasis: Impact Beyond the Skin
Generalized pustular psoriasis (GPP) is not only about the physical symptoms that impact people living with the condition. GPP goes deeper, beyond the skin.
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.
Lung Diseases
Our Therapeutic Areas
Generalized pustular psoriasis: The importance of support and collaboration to promote advances in the GPP community
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
Boehringer Shows Support for Children with Skin Conditions
This year, Boehringer Ingelheim joined campers at Camp Discovery in Millville, PA to demonstrate its support for those facing chronic skin conditions.
Prescription Digital Therapeutics a New Frontier in Mental Health Care
Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.
3 Ways Boehringer Ingelheim's Corporate Values Align with Hispanic Heritage
3 Ways Boehringer Ingelheim's Corporate Values Align with Hispanic Heritage
Helping a Local Community in a Time of Need
Helping a Local Community in a Time of Need
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Big Little Things: In cancer, small things make a big impact
Little things can be a big deal when you are living with or treating cancer. “Big Little Things” celebrates the small things that have a big impact.
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*
FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*
Update on LUME-Meso Clinical Trial
Click here to read an update on the LUME-Meso clinical trial, comparing nintedanib with other treatment options for malignant pleural mesothelioma.
Exploring beyond boundaries for innovation in animal health
Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.
Sustainable Development for Generations | Boehringer Ingelheim US
At BI, Sustainable Development – For Generations is about a journey. One that started in 1885 and one that we hope, and believe, will never end.
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders